1H-LSD

1H-LSD
Legal status
Legal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Under Psychoactive Substances Act
  • US: Unscheduled (may be covered by the Federal Analogue Act if sold for human consumption)
  • UN: Unscheduled
Identifiers
IUPAC name
  • (6aR,9R)-N,N-diethyl-6-methyl-4-hexanoyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
PubChem CID
Chemical and physical data
FormulaC26H35N3O2
Molar mass421.585 g·mol−1
3D model (JSmol)
SMILES
  • CN1CC(C=C2[C@H]1Cc1cn(C(=O)CCCCC)c3cccc2c31)C(=O)N(CC)CC
InChI
  • InChI=InChI=1S/C26H35N3O2/c1-5-8-9-13-24(30)29-17-18-15-23-21(20-11-10-12-22(29)25(18)20)14-19(16-27(23)4)26(31)28(6-2)7-3/h10-12,14,17,19,23H,5-9,13,15-16H2,1-4H3/t19?,23-/m1/s1
  • Key:RSBBZALMPUUEKF-LEQGEALCSA-N

1H-LSD (N1-hexanoyl-lysergic acid diethylamide, SYN-L-027)[1] is an acylated derivative of lysergic acid diethylamide (LSD), with a six carbon hexanoyl chain attached to the N1 position. It acts as a prodrug for LSD, and in animal studies produces drug-appropriate responding with a similar potency to short-chain homologues such as ALD-52 and 1P-LSD, in contrast to the 4 and 5 carbon homologues 1B-LSD and 1V-LSD which are several times weaker.[2]

See also

References

  1. ↑ WO 2024028495, Stratford A, Williamson JP, "Prodrugs of Substituted Ergolines", published 8 February 2024, assigned to Synex Holdings BV
  2. ↑ Brandt SD, Kavanagh PV, Gare S, Stratford A, Halberstadt AL (July 2024). "Analytical and behavioral characterization of 1-hexanoyl-LSD (1H-LSD)" (PDF). Drug Testing and Analysis. doi:10.1002/dta.3767. PMID 38965834.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.